PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite the positive aspects such as FDA feedback, ongoing partnerships, and financial readiness, the increased net loss, rising expenses, and management's vague responses in the Q&A raise concerns. Additionally, the lack of immediate revenue-driving catalysts and the absence of market cap data suggest a limited immediate impact on stock price, resulting in a neutral sentiment.
Key Financial Performance
Research and Development Expenses (Q4 2025) $6.2 million, a decrease from $7 million in Q4 2024. This decrease primarily reflects the completion of the SHIELD II Phase III trial and the transition towards regulatory submission and preparation activities.
General and Administrative Expenses (Q4 2025) $1.8 million, an increase from $1 million in Q4 2024. This increase was primarily due to noncash expenses relating to the vesting of performance-based options following the successful completion of the SHIELD II Phase III trial.
Marketing and Business Development Expenses (Q4 2025) $0.6 million, an increase from $0.2 million in Q4 2024. This increase reflects increased business development and commercial preparation efforts.
Net Loss (Q4 2025) $8.5 million or $0.41 per share, unchanged from $8.5 million in Q4 2024, but the loss per share decreased from $1.13 per share in Q4 2024 due to a higher number of shares outstanding.
Research and Development Expenses (Full Year 2025) $23.8 million, an increase from $22.8 million in 2024. This increase was primarily driven by continued activities related to the completion of the SHIELD II Phase III trial as well as regulatory preparation efforts and advancement of development programs.
General and Administrative Expenses (Full Year 2025) $7.2 million, an increase from $4.3 million in 2024. This increase was primarily due to noncash expenses relating to the vesting of performance-based options following the successful completion of the SHIELD II Phase III trial.
Marketing and Business Development Expenses (Full Year 2025) $2 million, an increase from $0.9 million in 2024. This increase reflects increased business development and commercial preparation efforts.
Net Loss (Full Year 2025) $34.2 million or $2.09 per share, an increase from $29 million or $4.91 per share in 2024. The loss per share decreased due to a higher number of shares outstanding.
Cash, Cash Equivalents, and Short-term Deposits (as of December 31, 2025) $12.9 million. Subsequent to the end of the quarter, $3.7 million in additional gross proceeds were generated from the exercise of warrants by long-time shareholders.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
D-PLEX100: Successfully completed SHIELD II Phase III trial with positive results, meeting primary and secondary endpoints, and reducing surgical site infections. Advanced into final stages of regulatory preparation with plans for a rolling NDA submission by Q1 2026.
Kynatrix Technology: Introduced as next-generation technology expanding beyond localized delivery to systemic therapeutic needs, including metabolic diseases like GLP-1 Receptor Agonist program.
U.S. Commercial Partnerships: Advanced discussions with potential U.S. partners experienced in hospital-based commercialization and surgical ecosystems. Progress reflects recognition of D-PLEX100's clinical profile and unmet needs.
Corporate Branding: Refreshed corporate brand to reflect transition from R&D to commercialization, targeting broader stakeholders like surgeons, pharmacists, and hospital administrators.
Financial Position: Ended 2025 with $12.9 million in cash and additional $3.7 million from warrant exercises. Current resources expected to fund operations into H2 2026.
Leadership Update: Appointed Brooke Story as Chairman of the Board, leveraging her experience in medical technology and surgical solutions to guide commercialization efforts.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory hurdles: The company is in the final stages of regulatory preparation for D-PLEX100, including a rolling NDA submission. While the FDA has provided positive feedback, regulatory approval processes are inherently uncertain and could delay commercialization.
Commercialization readiness: The company is transitioning from an R&D-focused organization to one preparing for commercialization. This shift involves significant operational and strategic challenges, including engaging with surgeons, pharmacists, hospital administrators, and potential commercial partners.
Financial sustainability: The company reported a net loss of $34.2 million for 2025 and has $12.9 million in cash reserves as of December 31, 2025. While additional funds were raised through warrant exercises, existing cash resources are only expected to fund operations into the second half of 2026, creating financial pressure.
Market competition: The company is entering a competitive market for surgical site infection prevention, which may impact the adoption and success of D-PLEX100 despite its differentiated value proposition.
Strategic execution risks: The company is advancing U.S. partnership discussions and preparing for commercialization, but delays or failures in securing partnerships could impact its strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Regulatory Pathway for D-PLEX100: PolyPid plans to begin the rolling NDA submission for D-PLEX100 by the end of Q1 2026. The FDA has provided positive feedback, supporting the company's clinical data package and regulatory pathway.
Commercial Partnerships: Advanced discussions are ongoing with potential U.S. commercial partners experienced in hospital-based commercialization and surgical ecosystems. These discussions are becoming increasingly detailed and operational.
Market Preparation: PolyPid is actively preparing for the commercialization of D-PLEX100, including engaging with surgeons, pharmacists, hospital administrators, and value committee members. The company is also building awareness through clinical engagement and webinars.
Financial Outlook: Existing cash resources are expected to fund operations into the second half of 2026, covering significant milestones.
Technological Advancements: The introduction of Kynatrix technology expands PolyPid's capabilities beyond localized delivery to systemic therapeutic needs, with a focus on metabolic diseases and other modalities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the current expectations for the proposed label for D-PLEX100?
A:The initial label is targeted for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, supported by SHIELD II Phase III data and breakthrough therapy designation. There may be opportunities for label expansion into broader abdominal surgical applications during the review process.
Q:What are the plans for broader label expansion and further opportunities for D-PLEX100?
A:The company plans to meet with the FDA to discuss broader label expansion opportunities. However, the focus remains on the current regulatory and commercialization pathway for D-PLEX100.
Q:What are the future applications for the platform and how do they differ from current formulations?
A:The company is expanding D-PLEX into other indications, with a near-term focus on regulatory and commercialization pathways. They are also working on a metabolic program leveraging their technology platform for long-term exposure of around 60 days, with additional data expected midyear.
Q:What work is being done to prepare for the potential approval of D-PLEX100?
A:Preparations include new branding, website updates, packaging work, market research on pricing, creating awareness through abstracts and articles, building a KOL network, and health economics studies. The company is also engaging with experienced global partners for market access and prior approval meetings in hospitals.
Q:What is the strategy for the GLP-1 program and its differentiation in the market?
A:The GLP-1 program uses the Kynatrix technology for approximately 60 days of sustained release, targeting improved patient compliance. The company aims to partner at an early stage and is building robust preclinical efficacy and PK data to support the program.
Q:What factors are important in identifying a U.S. commercial partner for D-PLEX100?
A:The ideal partner should have broad hospital-based capabilities and presence in the surgical suite. The company is advancing discussions with partners experienced in hospital networks and commercialization activities.
Q:What feedback has the FDA provided regarding the Phase III study and NDA pathway?
A:The FDA provided positive feedback, confirming the NDA pathway and indicating that the existing clinical data package is sufficient to support an NDA submission.
Q:What is the expected timeline for D-PLEX100's inclusion in hospital formularies post-approval?
A:The process involves educating surgeons, P&T reviews, pilot studies, and system updates. Uptake may take a few months, but once on formulary, usage is expected to grow steadily.
Q:When is the rolling submission for the NDA expected to be completed?
A:The NDA is expected to be submitted by the end of the first quarter, with the CMC and nonclinical module submitted first, followed by the clinical module within a couple of months.
Q:What are the differences between the Kynatrix platform and D-PLEX technology platform?
A:Kynatrix collects work on peptide release, intratumoral injection, and STING agonist partnerships under one umbrella, building new IP and allowing for more open discussion. The work has been a continuous development from the D-PLEX platform.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timeline for broader label expansion discussions with the FDA, the exact percentage of IDNs likely to include D-PLEX on formulary within the first 12 months, and the specific factors influencing the finalization of a U.S. commercial partner.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Agonist program
Dr
Full Conference
GLP Receptor
III result
Kynatrix technology
Kynatrix term
PLEX discussion
Phase III
PolyPid Full
RD commercialization
Receptor Agonist
brand
capability
chapter update
commercialization readiness
conversation stage
engagement
evolution
introduction Kynatrix
leader
life
opportunity PolyPid
pathway PLEX
potential PolyPid
progress discussion
structure
submission end
submission pathway
technology delivery
term opportunity
transition
unmet
PYPD Transcript
PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript
Unknown2-11
Despite the positive aspects such as FDA feedback, ongoing partnerships, and financial readiness, the increased net loss, rising expenses, and management's vague responses in the Q&A raise concerns. Additionally, the lack of immediate revenue-driving catalysts and the absence of market cap data suggest a limited immediate impact on stock price, resulting in a neutral sentiment.
PolyPid Ltd. (PYPD) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call highlights positive developments like successful inspections, strong market interest, and strategic partnerships. Despite increased expenses, the company shows financial improvement and a strong cash position. The Q&A reveals confidence in FDA processes and pricing strategies. The market opportunity for D-PLEX100 is significant, with plans for expansion and premium pricing potential. While some details were unclear, the overall sentiment is positive, suggesting potential stock price growth in the short term.
PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call reveals mixed signals: positive developments like the completion of Phase 3 trials and a strong cash position are offset by increased expenses and net losses. The Q&A highlights uncertainties in the GLP-1 program and partnership milestones. While the company has a promising product and strategic initiatives, financial challenges and competitive market risks temper enthusiasm. Given these factors, the stock price is likely to remain stable, reflecting a neutral sentiment.
PolyPid Ltd. (NASDAQ:PYPD) Q1 2025 Earnings Call Transcript
Unknown5-15
The earnings call presents a mixed picture. Financial health shows a net loss increase, raising concerns about sustainability, but the cash runway is extended into Q3 2025. The SHIELD II trial's positive signals and potential NDA submission are promising, yet the lack of finalized pricing and partnership details introduces uncertainty. The Q&A highlighted preparation for NDA filing, but also revealed unclear management responses and potential market risks. Overall, the sentiment is neutral, reflecting both potential and uncertainty without a clear catalyst for significant short-term stock movement.
PYPD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
